Medical cannabis improved quality of life for inflammatory bowel disease patients in a UK registry | Research

The takeaway

A UK Medical Cannabis Registry case series of 76 IBD patients found significant improvements in disease-specific quality of life, anxiety, sleep, and general health at 1 and 3 months, with mostly mild side effects.

Gastroenterologists, IBD patients, medical cannabis prescribers

Significant quality-of-life improvements at 3 months with 21% mild adverse event rate

What the researchers found

Among 76 patients (51 Crohn's, 25 ulcerative colitis), median SIBDQ scores improved at both 1 and 3 months. EQ-5D-5L index values, GAD-7 anxiety scores, and sleep quality also improved significantly at 3 months (all p<0.050). Sixteen patients (21%) reported adverse events, mostly mild to moderate. Prior cannabis consumers showed greater improvement than cannabis-naive individuals.

Why it matters

While clinical trials have not shown cannabis affects IBD inflammation directly, these real-world data suggest meaningful quality-of-life improvements for patients with refractory symptoms.

The numbers in context

76 patients (51 Crohn's, 25 ulcerative colitis); significant improvement in SIBDQ, EQ-5D-5L, GAD-7, and SQS at 3 months (p<0.050); 21.05% adverse events, mostly mild to moderate

How the study worked

Case series from the UK Medical Cannabis Registry analyzing IBD patients prescribed cannabis-based medicinal products. Primary outcomes included changes from baseline in SIBDQ, GAD-7, SQS, and EQ-5D-5L at 1 and 3 months.

What this study cannot tell us

Uncontrolled case series with no placebo group. Small sample size. Short follow-up period. Registry data may reflect selection bias toward motivated patients. No objective inflammation biomarkers assessed.

How to read the evidence

Real-world registry data showing consistent improvements across multiple outcomes, but uncontrolled design without placebo comparison limits conclusions.

When this study was published

Published 2023

The bigger picture

The gap between preclinical promise and clinical trial results for cannabis in IBD may partly reflect outcome measurement. Quality-of-life improvements matter to patients even without measurable changes in inflammation markers.

Questions still open

Would these quality-of-life improvements persist long-term? Is the greater response in prior cannabis users due to familiarity with effects or self-selection of responders?

Common questions

Does medical cannabis help with inflammatory bowel disease?

In this UK registry study of 76 patients, cannabis-based products improved IBD-specific quality of life, anxiety, sleep, and general health at 3 months, though no objective inflammation measures were assessed.

What side effects did IBD patients experience from medical cannabis?

About 21% reported adverse events, but the majority were classified as mild to moderate in severity. No serious adverse events were highlighted.

Read the original research

The effect of medical cannabis in inflammatory bowel disease: analysis from the UK Medical Cannabis Registry.

Expert review of gastroenterology & hepatology, 17(1), 85-98

View on PubMed ↗Publisher’s paper ↗

Citation

Dalavaye, Nishaanth; Erridge, Simon; Nicholas, Martha; Pillai, Manaswini; Bapir, Lara; Holvey, Carl; Coomber, Ross; Rucker, James J; Hoare, Jonathan; Sodergren, Mikael H. (2023). The effect of medical cannabis in inflammatory bowel disease: analysis from the UK Medical Cannabis Registry.. Expert review of gastroenterology & hepatology, 17(1), 85-98. https://doi.org/10.1080/17474124.2022.2161046